Business Context and Reporting Period
This Form 6-K is filed by Prima BioMed Ltd (noted as IMMUTEP Ltd in request metadata) on June 7, 2016. The registrant is a foreign private issuer based in Sydney, Australia, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification regarding listing status rather than a financial report.
Material Changes
The primary material event disclosed is the company's confirmation that it will maintain its listing on the NASDAQ stock market.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of maintaining the NASDAQ listing. The filing does not contain specific financial guidance, outlook projections, or detailed risk factors beyond the context of maintaining exchange compliance.
Key Facts for Investor Verification
- Prima BioMed Ltd confirmed it will maintain its NASDAQ listing as of June 7, 2016.
- The filing contains no financial performance data or forward-looking financial guidance.
- The report was signed by Marc Voigt, Chief Executive Officer.